Disubstituted Indazoles as Potent Antagonists of the Integrin αvβ3
- 16 December 1999
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 43 (1) , 41-58
Abstract
A new series of indazole-containing αvβ3 integrin antagonists is described. Starting with lead compound 18a, variations in a number of structural features were explored with respect to inhibition of the binding of β3-transfected 293 cells to fibrinogen and to selectivity for αvβ3 over GPIIbIIIa, another RGD-binding integrin. Indazoles attached to a 2-aminopyridine or 2-aminoimidazole by a propylene linker at the indazole 1-position and to a diaminopropionate derivative via a 5-carboxylate amide provided the best potency with moderate selectivity. Several differences in the SAR of the diaminopropionate moiety were observed between this series and a series of isoxazoline-based selective GPIIbIIIa antagonists. Compound 34a (SM256) was a potent antagonist of αvβ3 (IC50 2.3 nM) with 9-fold selectivity over GPIIbIIIa.Keywords
This publication has 27 references indexed in Scilit:
- Selective αvβ3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury1:Cardiovascular Research, 1997
- Discovery of Potent Nonpeptide Vitronectin Receptor (αVβ3) AntagonistsJournal of Medicinal Chemistry, 1997
- The αvβ3 integrin “vitronectin receptor”The International Journal of Biochemistry & Cell Biology, 1997
- Recent advances in cell adhesion molecules and extracellular matrix proteins: potential clinical implicationsDrug Discovery Today, 1997
- Cell adhesion and angiogenesisTrends in Cell Biology, 1996
- Role of integrins in angiogenesisEuropean Journal of Cancer, 1996
- Section Review: Cardiovascular & Renal: Glycoprotein IIb/IIIa antagonistsExpert Opinion on Therapeutic Patents, 1996
- The role of αv-integrins in tumour progression and metastasisSeminars in Cancer Biology, 1996
- Approach to discovering novel therapeutic agents for osteoporosis based on integrin receptor blockadeBiopolymers, 1995
- Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six monthsThe Lancet, 1994